SUMMARY, EXPLANATION AND LIMITATIONS:
Epidermal Growth Factor Receptors (EGFR) are transmembrane glycoproteins expressed by various cell types. The known EGFR-proteins (EGFR1, 2, 3, and 4 or HER1, 2, 3, and 4) are highly homologous proteins. They belong to the receptor tyrosine kinase superfamily and are involved in signal perception and transduction. To fulfil this function they build homo- and heterodimers with each other. Usually EGFR1 is referred to as EGFR, whereas EGFR2 is referred to as Her2. Correspondingly, EGFR3 and EGFR4 are also called HER3 and HER4, respectively. The antibody of clone 2-1E1 recognises the human EGFR1, in the following referred to as EGFR. EGFR is highly overexpressed by a variety of human tumours such as breast and lung carcinomas, colon carcinomas and in tumours of the brain. In the light of new therapeutic options with small molecules and therapeutic antibodies, immunohistochemical detection of EGFR-overexpression has gained increasing importance over the last years.
Immunogen: Purified human EGFR.
Staining pattern: Cytoplasmic membrane.
Positive control: A431 cells, skin, placenta or squamous cell carcinoma.
This antibody is designed for the specific localization of human EGFR using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.
EGFR may be overexpressed in breast tumors, brain, bladder, lung, stomach, head and neck, esophagus, cervix, vulva, ovary and endometrium. It is found predominantly in squamous cell carcinomas. It is expressed in a high percentage of squamous cell carcinoma metastases in different locations and therefore its expression has been considered as an indicator of poor prognosis in these neoplasms.
In light of new therapeutic options with small molecules and therapeutic antibodies for immunohistochemical detection of EGFR overexpression has been gaining importance in recent years.